These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251 [TBL] [Abstract][Full Text] [Related]
28. [Sympatholytic effect of intra-arterial reserpine in sclerodermia and Raynaud's disease]. Acevedo A; Palacios JM; López R; Palma F Rev Med Chil; 1984 Jun; 112(6):553-8. PubMed ID: 6515168 [No Abstract] [Full Text] [Related]
29. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013 [TBL] [Abstract][Full Text] [Related]
30. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Anderson ME; Moore TL; Lunt M; Herrick AL Rheumatology (Oxford); 2007 Mar; 46(3):533-8. PubMed ID: 17018538 [TBL] [Abstract][Full Text] [Related]
31. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Thompson AE; Shea B; Welch V; Fenlon D; Pope JE Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437 [TBL] [Abstract][Full Text] [Related]
32. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)]. Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789 [TBL] [Abstract][Full Text] [Related]
33. Low molecular weight dextran in systemic sclerosis and Raynaud's phenomenon. Dodman B; Rowell NR Acta Derm Venereol; 1982; 62(5):440-2. PubMed ID: 6183899 [No Abstract] [Full Text] [Related]
34. Plethysmographical and clinical observations on Bricanyl therapy in Raynaud's phenomenon. Zabel J; Fyrand O; Thune P Acta Derm Venereol; 1974; 54(5):391-5. PubMed ID: 4138501 [No Abstract] [Full Text] [Related]
35. [Griseofulvin administered for an indeterminate time in the therapy of systemic scleroderma and Raynaud's syndrome]. Giordano M; Capelli L; Ara M; Tirri G Reumatismo; 1971; 23(2):82-92. PubMed ID: 5146109 [No Abstract] [Full Text] [Related]
36. [Diagnosis and clinical relevance of microcirculation disorders in progressive scleroderma]. Brenke A; Brenke R; Loreck D Dermatol Monatsschr; 1990; 176(1):27-33. PubMed ID: 2311789 [TBL] [Abstract][Full Text] [Related]
37. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871 [TBL] [Abstract][Full Text] [Related]
38. Laser-Doppler measurement of digital blood flow regulation in normals and in patients with Raynaud's phenomenon. Kristensen JK; Engelhart M; Nielsen T Acta Derm Venereol; 1983; 63(1):43-7. PubMed ID: 6191488 [TBL] [Abstract][Full Text] [Related]
39. Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit. Surwit RS; Gilgor RS; Duvic M; Allen LM; Neal JA Arch Dermatol; 1983 Sep; 119(9):733-5. PubMed ID: 6614959 [TBL] [Abstract][Full Text] [Related]
40. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders. Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]